Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting
| Autor: | Christian W. Hamm, Peter Jüni, Leonardo Bolognese, Luc Janssens, Scot Garg, Ton Slagboom, Ivo Petrov, Edouard Benit, Janusz Prokopczuk, Patrick W. Serruys, Maurizio Ferrario, Glassy Investigators, Marco Valgimigli, Pascal Vranckx, Dik Heg, Adel Aminian, Christoph Naber, Roberto Diletti, Christoph Liebetrau, Carlo Tumscitz, Eugene P. McFadden, Stephan Windecker, Krzysztof Bryniarski, Anna Franzone, Aleksander Zurakowski, Kurt Huber, Sergio Leonardi, Raffaele Piccolo, Paweł Buszman, Marcello Dominici, Philippe Gabriel Steg, Mathias Vrolix |
|---|---|
| Přispěvatelé: | Cardiology, Franzone, A., Mcfadden, E., Leonardi, S., Piccolo, R., Vranckx, P., Serruys, P. W., Benit, E., Liebetrau, C., Janssens, L., Ferrario, M., Zurakowski, A., Diletti, R., Dominici, M., Huber, K., Slagboom, T., Buszman, P., Bolognese, L., Tumscitz, C., Bryniarski, K., Aminian, A., Vrolix, M., Petrov, I., Garg, S., Naber, C., Prokopczuk, J., Hamm, C., Steg, P. G., Heg, D., Juni, P., Windecker, S., Valgimigli, M. |
| Rok vydání: | 2019 |
| Předmět: |
Male
Ticagrelor medicine.medical_specialty medicine.medical_treatment Coronary Artery Disease 030204 cardiovascular system & hematology Rate ratio Drug Administration Schedule 03 medical and health sciences Percutaneous Coronary Intervention 0302 clinical medicine Internal medicine Statistical significance medicine Clinical endpoint Humans Prospective Studies 030212 general & internal medicine Myocardial infarction 610 Medicine & health Aged Aspirin business.industry Dual Anti-Platelet Therapy adjudication Percutaneous coronary intervention Drug-Eluting Stents Middle Aged medicine.disease dual antiplatelet therapy Confidence interval Survival Rate Treatment Outcome Cardiology Female Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors Follow-Up Studies medicine.drug |
| Zdroj: | Journal of the American College of Cardiology, 74(18), 2223-2234. Elsevier Inc. |
| ISSN: | 0735-1097 |
| Popis: | Background: The GLOBAL LEADERS (GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation) study randomly assigned 15,991 patients undergoing percutaneous coronary intervention to 1-month dual antiplatelet therapy (DAPT) followed by 23-month ticagrelor monotherapy or conventional 12-month DAPT followed by 12-month aspirin. Apart from Q-wave myocardial infarction (MI), all study endpoints were analyzed as investigator reported. Objectives: This was a pre-specified ancillary study assessing whether experimental therapy is noninferior, and if met, superior, to conventional treatment for the coprimary efficacy endpoint of all-cause death, nonfatal MI, nonfatal stroke, or urgent target vessel revascularization and superior in preventing BARC 3 (Bleeding Academic Research Consortium) or 5 bleeding (coprimary safety endpoint) at 2 years with a 0.025 significance level to preserve nominal 5% alpha error. Methods: An independent clinical event committee adjudicated investigator-reported and eventually unreported events of 7,585 patients from the 20 top-enrolling participating sites. Results: The 2-year coprimary efficacy endpoint occurred in 271 (7.14%) and in 319 (8.41%) patients in the experimental and conventional groups, respectively (rate ratio [RR]: 0.85; 95% confidence interval [CI]: 0.72 to 0.99), fulfilling noninferiority (p noninferiority |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|